InsidersTradesSigma
Total declarations
Companies
▲ Purchases (1 ops.)
▼ Sales (4 ops.)
Insider track record
Board DirectorDisclosed buys
1
Disclosed sells
4
Not enough buy signals with a settled T+90 horizon to measure a track record yet.
Signal history
Explore the full record of transactions filed by HALE DAVID F, Director. Officer active across 3 companies, notably Dermata Therapeutics, Inc.. In total, 11 reports have been published. Breakdown: 1 buy · 4 sells. Total volume traded: €38k. History available since 30 June 2021. The latest transaction was filed on 23 February 2024 (Acquisition). Regulator: SEC (Form 4). All data is openly available.
Declarations11 total
78,741 sharesCommon StockSEC:0001654954-25-000690:0
714 shares@ US$9.0416.9% of flowCommon StockSEC:0001209191-24-004016:0
Ideal exit: 19 Nov 2024 (T+270)
30,155 shares0Common StockSEC:0001654954-22-013528:0
26,441 shares0Common StockSEC:0001654954-22-009455:0
15,466 shares0Common StockSEC:0000905718-22-000562:0
363 shares@ US$4.060250.0% of flowCommon StockSEC:0001209191-21-069092
363 shares@ US$4.060250.0% of flowCommon StockSEC:0001209191-21-069092:0
44,777 sharesCommon StockSEC:0000905718-21-001110:0
44,777 sharesCommon StockSEC:0000905718-21-001110
3,669 shares@ US$4.7541.6% of flowCommon StockSEC:0001209191-21-045049
3,669 shares@ US$4.7550.0% of flowCommon StockSEC:0001209191-21-045049:0
11 of 11 declarations
About HALE DAVID F
HALE DAVID F is a Director at Oncternal Therapeutics, Inc., Dermata Therapeutics, Inc., and BIOCEPT INC. In these roles, he participates in corporate governance and strategic decision-making. His expertise in the biopharmaceutical sector allows him to make significant contributions to board discussions, ensuring innovation and performance for the companies.
